Esketamine for depression: all studies (page 14)

Ketamine/esketamine treatment for resistant depression in children and adolescents: a PRISMA systematic review.

European child & adolescent psychiatry February 2026 Konstantinos N Fountoulakis, Paraskevi Tatsiopoulou, Athanasios Saitis et al.

Ketamine and esketamine have been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior in adults. The current paper aimed to systematically review the available data on their efficacy in children and adolescents. The MEDLINE was searched with the keyword 'esketamine' on July 5th, 2024 (by following the PRISMA statement)....

DOI: 10.1007/s00787-025-02897-1 Full text Esketamine Adolescents Children Resistant depression

Advances in antidepressant pharmacotherapy: phase 3 evidence and clinical perspectives.

Expert Opinion on Pharmacotherapy February 1, 2026 Alessandro Cuomo, Mario Pinzi, Andrea Fagiolini

Major depressive disorder (MDD) remains a leading global cause of disability, with substantial clinical and societal burden. Despite the wide availability of antidepressants, many patients experience inadequate response, partial remission, or treatment-resistant depression. Emerging pharmacological options beyond traditional monoaminergic agents have shown promise in phase 3 clinical trials,...

DOI: 10.1080/14656566.2026.2634195 Full text Esketamine Major depressive disorder Treatment-resistant depression Antidepressants +2

Multimodal rapid anti-depression: Esketamine combined with dexmedetomidine patient-controlled sleep for treatment-resistant depression - A retrospective study.

Journal of Affective Disorders January 30, 2026 Yao-Zu Li, Cai-Qun Zhao, Mu-Yan Zuo et al.

To evaluate the efficacy and safety of a multimodal rapid anti-depression therapy that combines esketamine treatment with dexmedetomidine patient-controlled sleep (PCSL) in patients with treatment-resistant depression (TRD). We retrospectively included 233 patients with TRD who received the multimodal treatment. Baseline clinical characteristics were collected. Follow-up assessments were...

DOI: 10.1016/j.jad.2026.121311 Full text Esketamine Treatment-resistant depression Dexmedetomidine Multimodal rapid anti-depression +1

Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial.

European journal of anaesthesiology January 29, 2026 Tiantian Chu, Xiaoling Peng, Keliang Wan et al. 2 citations

Postpartum depression (PPD) is a common complication after childbirth, especially in primiparae. This trial sought to evaluate whether prophylactic administration of esketamine during the perinatal period could prevent PPD in primiparae without predisposition to prenatal depression. A prospective, double-blind, multicentre, randomised controlled trial. Three academic hospitals. Primiparae...

DOI: 10.1097/EJA.0000000000002348 Full text

Combining Intranasal Esketamine and Electroconvulsive Therapy in Severe Treatment‑Resistant Depression: A Case Series.

The Journal of ECT January 29, 2026 Sergi López-rodríguez, Aida De Arriba-Arnau, José Manuel Menchón et al. 1 citation

This case series describes the combined use of electroconvulsive therapy (ECT) and intranasal esketamine (ESK)-2 rapidly acting, evidence-based options for treatment-resistant depression (TRD). Each can leave residual symptoms or early relapse. Whether concurrent use confers more durable benefit remains unclear. We followed 4 adults (50 to 72 y) with severe TRD who had shown partial or waning...

DOI: 10.1097/yct.0000000000001233 Full text Esketamine Treatment-resistant depression Case series Combination therapy +2

Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents.

Expert Opinion on Therapeutic Targets January 28, 2026 Gia Han Le, Roger S McIntyre 1 citation

Up to 50% of adults with major depressive disorder (MDD) fail to achieve remission after two or more monoaminergic antidepressants and meet criteria for treatment-resistant depression (TRD). Low-dose intravenous ketamine, intranasal esketamine, and oral dextromethorphan represent the first glutamatergic treatments to exhibit rapid and robust efficacy in persons with TRD, yet their precise...

DOI: 10.1080/14728222.2026.2619757 Full text Treatment-resistant depression Esketamine Nmda receptor subunits Antidepressant mechanisms +2

Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.

Journal of Affective Disorders January 28, 2026 Clara De Oliveira Lapa, Thiago Viola, Rodrigo Delfino et al. 3 citations

Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generalizability of these findings to clinical practice remains unclear. This systematic review and meta-analysis aimed to synthesize real-world evidence of intranasal esketamine in patients with treatment-resistant depression. A systematic search was...

DOI: 10.1016/j.jad.2026.121257 Full text Esketamine Treatment-resistant depression Intranasal Meta-analysis +2

Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions.

BJPsych Open January 23, 2026 Nawfel Ayad, Karim Abdel Aziz, Samer Makhoul et al. 2 citations

Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce. This study aimed to evaluate the long-term effectiveness and side-effects of intranasal esketamine...

DOI: 10.1192/bjo.2025.10950 Full text Treatment-resistant depression Esketamine Long-term effectiveness Maintenance therapy +1

Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation.

Journal of Neuroinflammation January 22, 2026 Ang Liu, Xiao-Qi Zhang, Jia-Xin Guo et al.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and depression frequently co-occur, yet the biological basis of this comorbidity and effective therapeutic strategies remain poorly defined. METHODS: We established a rat model of COPD-depression comorbidity through sequential cigarette-smoke exposure and chronic unpredictable mild stress. Pulmonary function, depression-like behaviors,...

DOI: 10.1186/s12974-026-03699-1 Full text Depression Esketamine Animals Rats, sprague-dawley +8

Transforming treatment-resistant depression (TRD) care in the Gulf Cooperation Council (GCC) countries: a narrative review of emerging therapies, advancements, and implementation barriers.

Annals of General Psychiatry January 21, 2026 Mohammed A Alhassan

Treatment-resistant depression (TRD) remains a major clinical challenge worldwide and across the Gulf Cooperation Council (GCC) countries, where the burden of mental health disorders continues to rise. Conventional TRD therapies, including antidepressants, augmentation strategies, and electroconvulsive therapy (ECT), often result in incomplete remission and are associated with significant...

DOI: 10.1186/s12991-025-00626-1 Full text Esketamine Treatment-resistant depression Antidepressant therapies Gcc mental health +2

Research